Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine.

Journal: The British journal of ophthalmology
PMID: 37775259

Abstract

AIM: To predict antivascular endothelial growth factor (VEGF) treatment requirements, visual acuity and morphological outcomes in neovascular age-related macular degeneration (nAMD) using fluid quantification by artificial intelligence (AI) in a real-world cohort.

Authors

  • Virginia Mares
    Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
  • Ursula Margarethe Schmidt-Erfurth
    Department of Ophthalmology and Optometry, Medical University of Vienna, Wien, Austria ursula.schmidt-erfurth@meduniwien.ac.at.
  • Oliver Leingang
    Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
  • Philipp Fuchs
    Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
  • Marcio B Nehemy
    Department of Ophthalmology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Hrvoje Bogunović
    Christian Doppler Laboratory for Ophthalmic Image Analysis (OPTIMA), Department of Ophthalmology, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria.
  • Daniel Barthelmes
    Department of Ophthalmology, University of Zurich Faculty of Medicine, Zurich, Switzerland.
  • Gregor S Reiter
    Department of Ophthalmology and Optometry, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. gregor.reiter@meduniwien.ac.at.

Keywords

External Resources

Popular Topics
Recent Journals